Antibodies News and Research

RSS

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today.

24 Sep 2021

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

A recent study supports the efficacy of the mRNA-1273 vaccine in preventing COVID-19 illness and disease severity.

24 Sep 2021

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

A new study presents initial results from a randomized, placebo-controlled phase 1/2 trial in Thailand.

24 Sep 2021

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.

24 Sep 2021

Presumed immunity in US remains below the threshold sufficient to disrupt SARS-CoV-2 transmission

Researchers have investigated publicly available data published to investigate the proportion of the US population that has become immune to SARS-CoV-2.

24 Sep 2021

No excess mortality during the Delta variant era in US state with high vaccination rates

Researchers have investigated the number of excess deaths during the initial spread of the Delta variant.

24 Sep 2021

A daily pill to treat covid could be just months away, scientists say

Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.

24 Sep 2021

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

In a study recently published on the medRxiv* preprint server, scientists from Singapore have assessed the levels of IgA-specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the breast milk of women recently immunized with the second dose of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

24 Sep 2021

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Natural infection or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confer considerable protection against reinfection and reduce the risk of severe Coronavirus disease 2019 (COVID-19) outcomes.

24 Sep 2021

COVID-19 vaccination and lactation

A new study evaluates the presence of antibodies in breastmilk and the immune responses of lactating women after vaccination of the COVID-19 vaccine.

23 Sep 2021

New methodology for evaluating transmissibility and competitive advantages of co-circulating SARS-CoV-2 variants

A new study examines how SARS-CoV-2 variants confer a competitive advantage on the virus, fueling further transmission and mortality.

23 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19.

23 Sep 2021

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

In a paper, the vaccine-induced cellular and immune response of MS patients receiving a range of therapies are assessed.

23 Sep 2021

Antibody kinetics in recovered COVID-19 patients

Researchers from Tel Aviv University have been examining the kinetics of antibodies in recovered COVID-19 patients.

23 Sep 2021

Biosimilar drugs are cheaper than biologics. Are they similar enough to switch?

It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain, digestion problems, fatigue, and hot, red rashes.

23 Sep 2021

McLean wins NIH grant to explore links between COVID-19 vaccine and menstrual cycle changes

In research that will add important data to the experience of vaccines on women's health, Laura Payne, PhD, director of McLean Hospital's Clinical and Translational Pain Research Laboratory, has received a grant from the National Institutes of Health to explore potential links between SARS-CoV-2 vaccination and menstrual cycle changes.

23 Sep 2021

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Researchers in Canada, Italy, and the United States have encouraged extending the interval time between two doses of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine among individuals who have not previously been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2021

Antibodies News and Research

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Presumed immunity in US remains below the threshold sufficient to disrupt SARS-CoV-2 transmission

No excess mortality during the Delta variant era in US state with high vaccination rates

A daily pill to treat covid could be just months away, scientists say

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

COVID-19 vaccination and lactation

New methodology for evaluating transmissibility and competitive advantages of co-circulating SARS-CoV-2 variants

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Antibody kinetics in recovered COVID-19 patients

Biosimilar drugs are cheaper than biologics. Are they similar enough to switch?

McLean wins NIH grant to explore links between COVID-19 vaccine and menstrual cycle changes

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News